Engrailed-2 as a novel biomarker for prostate cancer
Gómez E. Gómez, Raúl M. Luque(Instituto de Salud Carlos III), Mireia Moreno, Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Rosa J. Valero, Sergio Pedraza‐Arévalo(Instituto Maimónides de Investigación Biomédica de Córdoba), Julia Carrasco‐Valiente(Instituto Maimónides de Investigación Biomédica de Córdoba), M.J. Requena-Tapia(Instituto Maimónides de Investigación Biomédica de Córdoba), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Daniel Hormaechea‐Agulla(Baylor College of Medicine), Juan Castano, J.P. Campos-Hernández
Cited by 0
Related Papers
Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3
|Brain|2020|103
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
|Cancer Letters|2015|91
Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight
|Journal of Endocrinology|2013|88
A Cellular and Molecular Basis for the Selective Desmopressin-Induced ACTH Release in Cushing Disease Patients: Key Role of AVPR1b Receptor and Potential Therapeutic Implications
|The Journal of Clinical Endocrinology & Metabolism|2013|81
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
|Journal of Endocrinology|2016|74